Catalyst calendar
Data as of 2026-08-19 16:00 UTC · tracked universe polled every 15 minutes
Three kinds of date: a PDUFA date (the deadline the FDA sets itself to decide on a drug application), an AdCom (an FDA advisory-committee meeting that reviews it in public), and a readout window (when a trial's results are expected). Dates marked confirmed by the company come from an 8-K or press-release quote; our estimate is a rule-derived window off the trial's registered primary-completion date (see methodology) — never shown the same way. Today: 200 estimated readout windows and 0 disclosed PDUFA/AdCom dates.
Next 7 days
| Date | Ticker | Phase | Event |
|---|---|---|---|
| 2027-03-05 in 28w | $VRTX | Phase 1 | A Phase 1, First-in-human Study of VX-433 NCT07584434 |
| 2027-03-12 in 29w | $VRTX | Phase 1 | A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type… NCT05791201 |
| 2027-03-23 in 31w | $VRTX | Phase 1 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in… NCT07437105 |
| 2027-03-25 in 31w | $REGN | Phase 1 | Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult… NCT07759167 |
| 2027-03-25 in 31w | $REGN | Phase 1 | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women… NCT04590326 |
| 2027-03-27 in 31w | $INCY | Phase 1 | A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic… NCT06818812 |
| 2027-04-12 in 34w | $ZEAL | Phase 1 | Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function NCT07682818 |
| 2027-04-13 in 34w | $INCY | Phase 1 | A Study to Assess the Safety and Pharmacokinetics of INCB123667 When… NCT07559474 |
| 2027-04-14 in 34w | $BMRN | Phase 1 | A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and… NCT06280209 |
| 2027-04-27 in 36w | $ALNY | Phase 1 | A Study to Evaluate ALN-2232 in Participants With Obesity NCT07463846 |
| 2027-04-30 in 36w | $INCY | Phase 1 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis… NCT04279847 |
| 2027-05-10 in 38w | $REGN | Phase 1 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With… NCT03564340 |
| 2027-05-15 in 38w | $REGN | Phase 1 | A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic… NCT06836609 |
| 2027-06-25 in 44w | $BIIB | Phase 1 | A Study to Find Out How Nusinersen is Processed in the Body When Given Through… NCT06555419 |
| 2027-07-31 in 49w | $ALNY | Phase 1 | A Study to Evaluate ALN-4915 in Adult Healthy Volunteers NCT07535606 |
| 2027-08-31 in 54w | $ALNY | Phase 1 | A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in… NCT06845202 |
| 2027-09-29 in 58w | $VIR | Phase 1 | Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in… NCT05997615 |
| 2027-09-30 in 58w | $ALNY | Phase 1 | A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma NCT06600321 |
| 2027-11-30 in 67w | $SRPT | Phase 1 | A First-in-human Study of the Effects of SRP-1005 in Participants With… NCT07536061 |
| 2027-12-14 in 69w | $ALNY | Phase 1 | A Study to Evaluate ALN-6222 in Participants With Obesity NCT07624071 |
| 2027-12-30 in 71w | $BEAM | Phase 1 | A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of… NCT06735755 |
| 2027-12-31 in 71w | $SRPT | Phase 1 | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From… NCT04626674 |
| 2028-01-05 in 72w | $ALNY | Phase 1 | A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary… NCT06659640 |
| 2028-01-17 in 74w | $AGIO | Phase 1 | A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and… NCT07241234 |
| 2028-06-19 in 96w | $BIIB | Phase 1 | A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it… NCT07662148 |